Keywords
Atenolol
Infant
How to Cite
Abstract
Infantile hemangiomas (IH) are the most common benign tumors of childhood. They typically appear within the first weeks of life and follow a natural course of proliferation and involution. Most IHs resolve spontaneously without intervention; however, a small number of cases with complications or located in high-risk areas may require treatment. Propranolol is the first-line therapy, but some patients experience undesirable side effects during treatment (bronchial hyperactivity, hypoglycemia, sleep disturbances). Atenolol has emerged as a therapeutic alternative with a favorable safety and efficacy profile for patients who develop adverse effects to propranolol. We report the case of an infant with IH successfully treated with atenolol.
References
International Society for the Study of Vascular Anomalies. ISSVA Classification. Milwaukee, WI: ISSVA, 2024. Disponible online: https://www.issva.org/classification. (Consulta: 10 octubre 2024).
Rodríguez A, Sebaratnam D, Wargon O, Wong L. Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol 2021; 85(6):1379-92. doi: 10.1016/j.jaad.2021.08.019.
Calderón X, Velásquez F, Castro R, Ballona R. Oral atenolol for infantile hemangioma: case series of 46 infants. Actas Dermosifiliogr (Engl Ed) 2020; 111(1):59-62. doi: 10.1016/j.ad.2019.03.015.
Cheirif O, Novelo A, Orozco L, Sáez M. Infantile hemangioma: an update in the topical and systemic treatments. Bol Med Hosp Infant Mex 2019; 76(4):167-75. doi: 10.24875/BMHIM.19000002.
Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol 2015; 172(1):24-32. doi: 10.1111/bjd.13388.
Ábarzúa A, Navarrete C, Heusser F, Retamal J, Zegpi M. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol 2014; 70(6):1045-9. doi: 10.1016/j.jaad.2014.01.905.
Raphael M, Breugem C, Vlasveld F, de Graaf M, Slieker M, Pasmans S, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: a cohort study. J Am Acad Dermatol 2015; 72(3):465-72. doi: 10.1016/j.jaad.2014.12.019.
Starkey E, Shahidullah H. Propranolol for infantile haemangiomas: a review. Arch Dis Child 2011; 96(9):890-3. doi: 10.1136/adc.2010.208884.
Pattanshetti S, Mahalmani V, Sarma P, Kaur H, Ali M, Malik M, et al. Oral atenolol versus propranolol in the treatment of infantile hemangioma: a systematic review and meta-analysis. J Indian Assoc Pediatr Surg 2022; 27(3):279-86. doi: 10.4103/jiaps.jiaps_3_21.
Sociedad Argentina de Dermatología. Consenso sobre hemangiomas infantiles 2016. Buenos Aires: SAD, 2016. Disponible online: https://sad.org.ar/wp-content/uploads/2019/09/HEMANGIOMAS-INFANTILES-FINAL-corregido-fe-de-erratas-30112017.pdf. (Consulta: 10 octubre 2024).
Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2021; 147(7):599-607. doi: 10.1001/jamaoto.2021.0454.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Archives of Pediatrics of Uruguay